NRAS G13V

CI-VAR-00001640Explore in graph →CIViC 1317

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma1
NRAS G13V	Cetuximab	Predictive	B	Supports Resistance	2	submitted	EID3035 From 31 patients with advanced cutaneous squamous cell carcinomas evaluated for mutations in RAS, BRAF, and EGFR genes, only 2 RAS mutated samples (6.5%) were identified. Patients with NRAS p.G12D (c.… (full text at CIViC) PMID 28259104 · Picard et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.